• A 'Moderna for cancer immunotherapies,' developing novel drugs that harness the body's immune system to fight tumors.
• A 'specialized, clinical-stage Merck or Bristol Myers Squibb' dedicated to discovering and developing new immunotherapy drugs for cancer.

• Domvanalimab: An anti-TIGIT antibody developed to block the TIGIT immune checkpoint and enhance anti-tumor activity, particularly in cancer treatment.
• Zimberelimab: An anti-PD-1 antibody designed to block the PD-1 immune checkpoint and restore the body's anti-tumor T-cell response in cancer.
• Etrumadenant: A dual adenosine receptor antagonist (A2aR/A2bR) aimed at overcoming adenosine-mediated immune suppression within the tumor microenvironment to treat cancer.
• Quemadcirsen: An anti-CD73 antibody that inhibits CD73, thereby reducing immunosuppressive adenosine in the tumor microenvironment to fight cancer.

Arcus Biosciences (RCUS) is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. As such, the company primarily sells or partners with other companies, typically larger pharmaceutical firms, rather than directly to individuals.

Its major customer/strategic partner is:

• Gilead Sciences, Inc. (GILD)

Gilead Sciences has a comprehensive strategic collaboration with Arcus Biosciences, involving multiple oncology programs. This partnership includes significant equity investments, upfront payments, potential milestone payments, and royalties on future sales, making Gilead Sciences their primary financial collaborator and "customer" in the context of their business model.

null

Dr. Rosen has over 30 years of experience leading drug discovery and development organizations in the biotechnology and pharmaceutical industries. He co-founded Arcus Biosciences in 2015. Previously, Dr. Rosen co-founded and served as CEO of Flexus Biosciences, a company focused on small molecule drugs to reverse tumor immunosuppression, which was acquired by Bristol-Myers Squibb in 2015 for $1.25 billion. He held executive positions at Amgen and Tularik, and scientific and management positions at Pfizer and Abbott Laboratories. Dr. Rosen is also a co-inventor of SUTENT® (sunitinib), a significant drug for treating advanced renal cell carcinoma and other cancers.

Mr. Goeltz possesses an extensive background in finance and accounting. Most recently, he served as Chief Financial Officer and Senior Vice President of UNITY Biotechnology, and prior to that, as Chief Financial Officer of CytomX Therapeutics. In these roles, he was responsible for leading both companies' IPOs and finance organizations.

Ms. Jarrett is an accomplished executive with experience in the healthcare and technology sectors. She most recently served as Vice President of Corporate Development and Capital Markets at Uber Technologies, Inc. Prior to this, she was the Chief Operating Officer and Chief Financial Officer of Arcus Biosciences, where she played a significant role in leading Arcus's initial public offering. Before joining Arcus, Ms. Jarrett was the Chief Financial Officer of Medivation, a commercial oncology company that developed XTANDI® (enzalutamide), which was acquired by Pfizer in 2016. She also spent 20 years in investment banking, including running Citigroup's west coast life sciences investment banking practice.

Dr. Jaen has more than 30 years of experience in drug discovery and development. He co-founded Arcus Biosciences in 2015. Prior to Arcus, Dr. Jaen co-founded and was President of Flexus Biosciences. He also served as Chief Scientific Officer and Senior Vice President of Drug Discovery at ChemoCentryx for seven years. Dr. Jaen has held various positions at Amgen, Tularik, and Parke-Davis/Warner-Lambert. He is an inventor on 50 patents and has contributed to the advancement of over 20 novel molecules into clinical development.

Dr. Yingling joined Arcus Biosciences in 2020 as Senior Vice President, Research, after previously serving as a member of the Arcus Scientific Advisory Board. As part of the Research Leadership team, he is responsible for guiding all aspects of the company's research, discovery, and translational efforts, and establishing a key research interface with the Development organization.

One clear emerging threat for Arcus Biosciences is the highly competitive and evolving landscape of TIGIT inhibitors, a class of cancer immunotherapies where Arcus's lead asset, domvanalimab, is a primary focus. While Arcus (in partnership with Gilead Sciences) has presented promising data for domvanalimab in certain indications, the TIGIT inhibitor class has seen mixed clinical trial results across the industry, notably with Roche's tiragolumab experiencing setbacks in some pivotal trials. Despite these mixed signals, other major pharmaceutical companies, including Roche (with ongoing tiragolumab trials) and Merck (with vibostolimab), continue to develop their own TIGIT inhibitors or novel immunotherapy combinations.

The emerging threat lies in the possibility that a competitor's TIGIT inhibitor or an alternative novel immunotherapy targeting similar pathways could demonstrate definitively superior efficacy or safety, or achieve a faster regulatory approval in key cancer indications. Such an outcome from a rival could establish a new standard of care, significantly capturing market share and diminishing the commercial potential for Arcus's domvanalimab and related combination therapies, which are central to its pipeline and valuation.

Arcus Biosciences (RCUS) focuses on developing therapies for various cancers. The addressable markets for their main product candidates are as follows:

• Casdatifan (HIF-2a inhibitor) for Clear Cell Renal Cell Carcinoma (ccRCC): Analysts project sales for casdatifan in second-line renal cell carcinoma to be approximately $1.5 billion by 2034. This indicates a significant addressable market globally for this product within ccRCC.
• Domvanalimab (anti-TIGIT antibody) and Zimberelimab (anti-PD-1 antibody) for Non-Small Cell Lung Cancer (NSCLC): The global non-small cell lung cancer therapeutics market was valued at approximately USD 33.90 billion in 2024 and is projected to reach USD 66.04 billion by the end of 2032. North America holds a substantial share of this market, with a market revenue of USD 15.07 billion in 2024.
• Quemliclustat (CD73 inhibitor) for Pancreatic Cancer: The global pancreatic cancer treatment market size was estimated at USD 2.92 billion in 2024 and is projected to reach USD 5.84 billion by 2030. Other sources estimate the global pancreatic cancer market size to be around USD 3.25 billion in 2025, projected to surpass USD 10.25 billion by 2034. North America is a major contributor, holding more than 39% of the revenue share in 2025, with the U.S. market alone estimated at USD 887.25 million in 2025, and projected to reach around USD 2,854.37 million by 2034.
• AB598 (ANTI-CD39) for Gastrointestinal Cancer, including Colorectal Cancer: The global colorectal cancer therapeutics market size was estimated at USD 12.79 billion in 2024 and is projected to reach USD 19.95 billion by 2034. North America contributed the highest market share of 38% in 2024. The global colorectal cancer market is estimated to be valued at USD 13.74 billion in 2025 and is expected to reach USD 19.08 billion by 2032. North America is expected to lead this market, holding a 39.5% share in 2025.

Arcus Biosciences (RCUS) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer, with future revenue growth primarily tied to the successful advancement and commercialization of its pipeline candidates and strategic collaborations.

Here are 3-5 expected drivers of future revenue growth for Arcus Biosciences over the next 2-3 years:

1. Advancement and Potential Approval of Late-Stage Oncology Pipeline Candidates: Arcus Biosciences' lead pipeline assets, particularly casdatifan (HIF-2α inhibitor) for renal cell carcinoma (RCC), are significant drivers. The company initiated the pivotal Phase 3 PEAK-1 trial for casdatifan in combination with cabozantinib in immunotherapy-experienced RCC in Q2 2025, with more mature data expected in mid-2026. Additionally, domvanalimab (anti-TIGIT antibody) is in Phase 3 development for gastric cancer (STAR-221, with data expected in 2026) and non-small cell lung cancer, and quemliclustat (CD73 inhibitor) has received Orphan Drug Designation for pancreatic cancer. Successful clinical trial outcomes and subsequent regulatory approvals for these late-stage programs are crucial for unlocking projected multi-billion dollar market opportunities and driving significant future revenue.
2. Strategic Collaborations and Milestone Payments: Arcus maintains a significant collaboration with Gilead Sciences, which has historically provided revenue through license and development services, as well as upfront and milestone payments. Although a one-time revenue recognition event related to Gilead returning rights to a program significantly boosted 2025 GAAP revenue, ongoing and future milestone payments from existing and potentially new partnerships, such as the one with AstraZeneca for the eVOLVE-RCC02 trial of casdatifan, will continue to contribute to revenue.
3. Expansion into New Indications and Earlier Lines of Treatment: Arcus is actively exploring new applications for its drug candidates, such as evaluating casdatifan in earlier-line settings for RCC, including TKI-free regimens and combinations, which could substantially expand its addressable market. Similarly, the company is positioning domvanalimab and zimberelimab for combination treatments in first-line non-small cell lung cancer and gastric cancer, aiming to capture market share over existing therapies. Broadening the therapeutic scope and moving into earlier treatment lines for these cancers will be a key driver of increased patient populations and, consequently, revenue.
4. Development of New Pipeline Programs: Beyond its current oncology focus, Arcus has initiated preclinical development for programs in inflammatory and autoimmune diseases, with a small molecule targeting MRGPRX2 expected to enter the clinic in 2026. While further out, successful progression of these new programs into clinical stages and eventual commercialization could diversify Arcus's revenue streams and contribute to long-term growth beyond the immediate 2-3 year horizon.

Share Issuance

• In November 2025, Arcus Biosciences completed an underwritten equity offering, issuing 15,755,000 shares and generating net proceeds of approximately $269.7 million.
• In February 2021, Gilead Sciences purchased 5,650,000 additional shares of Arcus's common stock at $39.00 per share, increasing its ownership from approximately 13% to 19.5%.

Inbound Investments

• In May 2020, Arcus Biosciences entered a 10-year partnership with Gilead Sciences, which included a $175 million upfront payment and a $200 million equity investment from Gilead at $33.54 per share.
• Gilead Sciences made further equity investments, providing $320 million in January 2024 and a $100 million option continuation payment in July 2024.
• In October 2025, Taiho Pharmaceutical exercised an option for an exclusive license to casdatifan in Japan and certain other Asian territories, which will result in an option payment and potential milestone and royalty payments for Arcus.

Capital Expenditures

• Arcus Biosciences' capital expenditures are controlled, with manufacturing for clinical trials typically outsourced to contract manufacturing organizations.
• The company maintains substantial research and development expenditures, often exceeding $100 million per quarter, such as $111 million for the fourth quarter of 2024.
• Net proceeds from the November 2025 public offering are intended to fund ongoing research and development, including the expansion of the casdatifan clinical development program and the development of its immunology and inflammation portfolio.